Clinical Outcomes in Concurrent Cohorts of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA)-Treated versus ELX/TEZ/IVA-Ineligible Individuals with Cystic Fibrosis in the US during COVID-19.
Saved in:
| Title: | Clinical Outcomes in Concurrent Cohorts of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA)-Treated versus ELX/TEZ/IVA-Ineligible Individuals with Cystic Fibrosis in the US during COVID-19. |
|---|---|
| Authors: | Merlo, Christian A.1 (AUTHOR), Romdhani, Hela2 (AUTHOR), DerSarkissian, Maral2 (AUTHOR), Muthukumar, Aruna2 (AUTHOR), McGarry, Lisa J.3 (AUTHOR), Lou, Yiyue3 (AUTHOR), Van Brunt, Kate3 (AUTHOR) kate_vanbrunt@vrtx.com |
| Source: | Pulmonary Therapy. Jun2026, Vol. 12 Issue 2, p599-615. 17p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 23641746 |
|---|---|
| DOI: | 10.1007/s41030-026-00363-0 |
